文献速递糖尿病

GRADE队列中二甲双胍剂量优化对血糖和体重的影响

Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight.
PubMed 文献 · Diabetes Care · 2020-03-05

该研究对GRADE研究中6823例以二甲双胍为唯一降糖药的2型糖尿病患者进行预设分析,受试者完成4至14周(平均7.9±2.4周)的剂量优化导入期,二甲双胍调整至2000 mg/天或最大耐受较低剂量。结果显示,剂量增加≥1000 mg/天者HbA1c平均下降0.65±0.02%(-7.1±0.2 mmol/mol),剂量不变者下降0.48±0.02%(-5.2±0.2 mmol/mol),剂量减少者下降0.23±0.07%(-2.5±0.8 mmol/mol)。作者认为,将二甲双胍优化至2000 mg/天或最大耐受较低剂量并强调用药依从性和生活方式可改善血糖。

要点

  • 剂量增加≥1000 mg/天者HbA1c平均下降0.65±0.02%(-7.1±0.2 mmol/mol)。
  • 剂量不变者HbA1c平均下降0.48±0.02%(-5.2±0.2 mmol/mol)。
  • 剂量减少者HbA1c平均下降0.23±0.07%(-2.5±0.8 mmol/mol)。

核心结论

  • 将二甲双胍优化至2000 mg/天或最大耐受较低剂量,结合强调用药依从性和生活方式,可改善HbA1c≥6.8%(51 mmol/mol)的2型糖尿病患者的血糖。

研究设计与样本

  • 这是GRADE研究的预设分析,纳入6823例以二甲双胍为唯一降糖药的2型糖尿病患者,完成4至14周(平均7.9±2.4周)导入期,二甲双胍调整至2000 mg/天或最大耐受较低剂量。

主要发现

  • 调整导入期时长后,剂量增加≥1000 mg/天者(n=2169)HbA1c平均变化为-0.65±0.02%(-7.1±0.2 mmol/mol)。
  • 剂量不变者(n=3548)HbA1c平均变化为-0.48±0.02%(-5.2±0.2 mmol/mol)。
  • 剂量减少者(n=192)HbA1c平均变化为-0.23±0.07%(-2.5±0.8 mmol/mol)。
  • 单变量和多变量分析中,基线HbA1c越高预测HbA1c下降越大(P<0.001)。
  • 调整导入期时长后,剂量增加≥1000 mg/天者(n=1894)平均体重下降0.91±0.05 kg。

临床怎么用

  • 作者认为,将二甲双胍优化至2000 mg/天或最大耐受较低剂量并强调用药依从性和生活方式,可改善HbA1c≥6.8%(51 mmol/mol)的2型糖尿病患者的血糖。
  • 作者认为,这些发现可能有助于指导优化血糖控制欠佳的2型糖尿病患者的二甲双胍治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We evaluated the effect of optimizing metformin dosing on glycemia and body weight in type 2 diabetes. RESEARCH DESIGN AND METHODS: This was a prespecified analysis of 6,823 participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) taking metformin as the sole glucose-lowering drug who completed a 4- to 14-week (mean ± SD 7.9 ± 2.4) run-in in which metformin was adjusted to 2,000 mg/day or a maximally tolerated lower dose. Participants had type 2 diabetes for <10 years and an HbA1c ≥6.8% (51 mmol/mol) while taking ≥500 mg of metformin/day. Participants also received diet and exercise counseling. The primary outcome was the change in HbA1c during run-in. RESULTS: Adjusted for duration of run-in, the mean ± SD change in HbA1c was -0.65 ± 0.02% (-7.1 ± 0.2 mmol/mol) when the dose was increased by ≥1,000 mg/day, -0.48 ± 0.02% (-5.2 ± 0.2 mmol/mol) when the dose was unchanged, and -0.23 ± 0.07% (-2.5 ± 0.8 mmol/mol) when the dose was decreased (n = 2,169, 3,548, and 192, respectively). Higher HbA1c at entry predicted greater reduction in HbA1c (P < 0.001) in univariate and multivariate analyses. Weight loss adjusted for duration of run-in averaged 0.91 ± 0.05 kg in participants who increased metformin by ≥1,000 mg/day (n = 1,894). CONCLUSIONS: Optimizing metformin to 2,000 mg/day or a maximally tolerated lower dose combined with emphasis on medication adherence and lifestyle can improve glycemia in type 2 diabetes and HbA1c values ≥6.8% (51 mmol/mol). These findings may help guide efforts to optimize metformin therapy among persons with type 2 diabetes and suboptimal glycemic control.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Sivitz WI, Phillips LS, Wexler DJ, et al. Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. Diabetes Care. 2020. PMID: 32139384. doi:10.2337/dc19-1769

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。